Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · IEX Real-Time Price · USD
1.135
+0.005 (0.44%)
Apr 23, 2024, 9:38 AM EDT - Market open
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for RIGL stock have an average target of 5.81, with a low estimate of 1.25 and a high estimate of 15. The average target predicts an increase of 411.89% from the current stock price of 1.14.
Analyst Consensus: Buy
* Price targets were last updated on Mar 7, 2024.
Analyst Ratings
The average analyst rating for RIGL stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 3 | 3 | 3 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +252.42% | Mar 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $2 → $3 | Hold | Maintains | $2 → $3 | +164.32% | Mar 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,221.59% | Mar 6, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $1.25 | Hold | Maintains | $1.25 | +10.13% | Mar 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,221.59% | Feb 22, 2024 |
Financial Forecast
Revenue This Year
151.97M
from 116.88M
Increased by 30.02%
Revenue Next Year
196.01M
from 151.97M
Increased by 28.98%
EPS This Year
-0.07
from -0.14
EPS Next Year
0.09
from -0.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 168.2M | 228.3M | 279.6M | 235.2M | 272.9M |
| Avg | 152.0M | 196.0M | 232.5M | 203.8M | 208.9M |
| Low | 133.7M | 156.8M | 195.9M | 156.9M | 112.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 43.9% | 50.2% | 42.6% | 1.2% | 33.9% |
| Avg | 30.0% | 29.0% | 18.6% | -12.3% | 2.5% |
| Low | 14.4% | 3.2% | -0.1% | -32.5% | -44.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.04 | 0.19 | 0.46 | 0.25 | 0.36 |
| Avg | -0.07 | 0.09 | 0.24 | 0.16 | 0.23 |
| Low | -0.13 | -0.02 | 0.15 | 0.01 | 0.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 431.0% | 5.1% | 128.3% |
| Avg | - | - | 175.1% | -34.8% | 47.9% |
| Low | - | - | 68.6% | -95.9% | -81.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.